HighMark Wealth Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

HighMark Wealth Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,219	Closed	-$2.16M	–	584
2023 Q2	$2.16M	Sell	21,219 -50	-0.2%	-$4.73K	1.63%	8
2023 Q1	$1.93M	Buy	21,269 +11,588	+120%	+$680K	1.51%	8
2022 Q4	$368K	Buy	+9,681	New	+$333K	0.28%	33

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HighMark Wealth Management's RETA Position: Q3 2023 in Review

HighMark Wealth Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 21,219 shares — an estimated $2.16M sold.

HighMark Wealth Management first reported a position in RETA in Q4 2022 and held it in 3 quarters. The position peaked at $2.16M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

HighMark Wealth Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
HighMark Wealth Management sold 21,219 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.16M.
HighMark Wealth Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 3 quarters.
HighMark Wealth Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.16M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on HighMark Wealth Management's 13F filing for Q3 2023, filed 18 Oct 2023.